Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28433567 | 1.00 | CA2 (0.39) | CA2CA1MMEALDH1A1TP53 | |
| SCHEMBL17373361 | 1.00 | CA2 (0.39) | CA2CA1MMEALDH1A1TP53 | |
| SCHEMBL9341542 | 0.84 | ALDH1A1 (0.43) | CA2CA1MMEALDH1A1TP53 | |
| SCHEMBL9805189 | 0.84 | ALDH1A1 (0.43) | CA2CA1MMEALDH1A1TP53 | |
| SCHEMBL29538486 | 0.83 | CA2 (0.41) | CA2CA1MMEALDH1A1TP53 | |
| SCHEMBL684795 | 0.83 | L3MBTL1 (0.35) | ALDH1A1POLBMAPK1NPSR1L3MBTL1 | |
| SCHEMBL684475 | 0.83 | L3MBTL1 (0.35) | ALDH1A1POLBMAPK1NPSR1L3MBTL1 | |
| SCHEMBL17432119 | 0.83 | GAA (0.33) | ALDH1A1POLBMAPK1NPSR1L3MBTL1 | |
| SCHEMBL18329323 | 0.82 | TSHR (0.35) | CA2CA1MMETSHR | |
| SCHEMBL31683771 | 0.81 | CA2 (0.38) | CA2CA1MMEALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157909-B1 | LMP7 INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10654843-B2 | LMP7 inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180208589-A1 | LMP7 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-07-26 | — | — | US | disclosed |
| EP-3157909-A1 | LMP7 INHIBITORS | Principia Biopharma Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015195950-A1 | LMP7 INHIBITORS | PRINCIPIA BIOPHAMRAM INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208589-A1 | LMP7 INHIBITORS | PSMA7, PSMB7, PSMD7 | CA2 4104/4885CA1 2983/4885MME 428/4885 |
| US-10654843-B2 | LMP7 inhibitors | PSMA7, PSMB7, PSMD7 | CA2 4104/4885CA1 2983/4885MME 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.